DFC_MK-3475-598-03 (KEYNOTE)

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs Pembrolizumab plus Placebo in Previously Untreated, Stage IV, Metastatic Non-small Cell Lung Cancer Subjects Whose Tumors are PD-L1 Positive (TPS >=50%) (KEYNOTE-598)

Phase III
NCT03302234
Cancer
Lung
Raul Mena, M.D.
Merck
Jenny Bardens
  • Disney Family Cancer Center (DFCC)
  • Providence Los Angeles Research Center